MYRIAD GENETICS INC

Company Overview

Myriad Genetics (MYGN) is a genomics-driven molecular diagnostics provider focused on Oncology, Women’s Health and Pharmacogenomics, selling primarily in the U.S. (direct sales force ~500) and Japan with broader international distribution. Core products include FDA-approved companion diagnostics (BRACAnalysis CDx, MyChoice CDx), tumor profiling (Precise Tumor; Precise Liquid planned), MRD (Precise MRD), hereditary risk panels (MyRisk, Prolaris), prenatal screens (Prequel with AMPLIFY) and the GeneSight pharmacogenomics panel. The business is R&D‑intensive ($113.4M in 2024), operates multiple CLIA labs and is subject to substantial regulatory, reimbursement and licensing risk (including recent UnitedHealthcare coverage changes and ongoing LDT/FDA rule litigation). Seasonal testing volumes, lab consolidation, and reimbursement dynamics materially influence near‑term revenue, margins and cash flows.

Executive Compensation Practices

Given the science‑and commercialization‑heavy business model, compensation likely blends base salary with short‑term cash incentives tied to revenue per test, test volumes, and adjusted operating metrics (adjusted EBITDA or operating cash flow) and long‑term equity grants tied to multi‑year product and regulatory milestones (e.g., launches of Precise MRD/Precise Liquid/FirstGene) and total shareholder return. Management’s disclosures highlight non‑GAAP improvement efforts (cost of revenue % declines, commission restructuring), so incentive plans may now emphasize margin/cost‑per‑test and cash generation to reflect the firm’s liquidity focus after large impairment charges and tighter covenant risk. High R&D spend and the need to retain lab scientists during consolidation make retention awards and time‑based or milestone vesting common, and DEI/operational goals (workforce composition, NPS) may be used as secondary performance metrics. Expect compensation committees to incorporate downside protections and clawbacks tied to accounting impairments, material restatements or failure to achieve reimbursement/coverage milestones.

Insider Trading Considerations

Material events that are likely to drive insider trades at Myriad include payer coverage decisions (e.g., UnitedHealthcare policy changes), regulatory approvals or FDA/PMDA submissions, major clinical readouts or intellectual property/license outcomes, lab consolidation milestones and financing or covenant developments (ABL/OrbiMed facilities). Because these items are frequent and can be material, insiders commonly use pre‑arranged 10b5‑1 plans and will be subject to standard blackout windows around earnings, clinical readouts and major commercial announcements; watch for clustering of trades around quarter‑end seasonality (weaker Q1/Q3) and financing moves. Large insider purchases can signal confidence in recovery after impairment or reimbursement setbacks, while concentrated sales during liquidity stress or before covenant amendments merit closer scrutiny; researchers should track Form 4 filings, 10b5‑1 plan disclosures and any company preclearance policy notes tied to licensing or payer negotiations. Regulatory oversight (FDA LDT rules, CLIA, HIPAA) and active litigation increase the likelihood that material nonpublic information arises, so insider activity around those topics is especially informative.